maritide obesity drug news - Search News

Amgen, Obesity

The New York Times on MSN · 3d

New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month,

BioPharma Dive · 3d

Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

CNBC on MSN · 3d

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

3d

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

FierceBiotech3d

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent ...

3d

Amgen stock slips as obesity drug study disappoints Wall Street

Amgen (AMGN) fell sharply during Tuesday's intraday trading following the release of phase two trial results for its monthly ...

2d

Amgen’s MariTide: Hold Rating Amid Efficacy and Safety Concerns in Obesity Treatment

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results